SUCAMPO AG Patent applications |
Patent application number | Title | Published |
20160120840 | METHOD AND COMPOSITION FOR TREATING NONEROSIVE REFLUX DISEASE - Method and composition for treating a nonerosive reflux disease in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative are provided. | 05-05-2016 |
20150272961 | METHOD FOR TREATING MUCOSITIS, METHOD FOR TREATING TUMOR, AND PHARMACEUTICAL COMBINATION - Disclosed is a method for treating tumor in a mammalian subject, which comprises administering a combination of (a) an anti-tumor agent and (b) a fatty acid derivative represented by the formula (I): | 10-01-2015 |
20150126609 | PHARMACEUTICAL COMPOSITION COMPRISING 11-DEOXY -PROSTAGLANDIN COMPOUND AND METHOD FOR STABILIZING THE COMPOUND - Provided is a pharmaceutical composition including an 11-deoxy-prostaglandin compound represented by formula (I): | 05-07-2015 |
20150099802 | SELECTIVE TUMOR TREATMENT - A method for treating a tumor with a decreased level of the 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative, a method for suppressing the growth of a tumor cell with a decreased level of the 15-hydroxy-prostaglandin dehydrogenase (15-PGDH), which comprises contacting said tumor cell with an effective amount of a fatty acid derivative, and a method for identifying a subject who would be responsive to a fatty acid derivative, comprising, (i) obtaining a biological sample from said subject; and (ii) measuring 15-hydroxyprostaglandin dehydrogenase (15-PGDH) level are provided. | 04-09-2015 |
20150057351 | METHOD FOR TREATING NEUROPATHIC PAIN - A method for treating neuropathic pain in a mammalian subject, which comprises administering an effective amount of a fatty acid derivative, is provided. | 02-26-2015 |
20140371309 | OPHTHALMIC SOLUTION - The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient. | 12-18-2014 |
20140371304 | METHOD FOR SUPPRESSING TUMORIGENICITY OF STEM CELLS - A method for suppressing tumorigenicity of stem cells in a mammalian subject, which comprises administering an effective amount of a fatty acid derivative and a method for suppressing tumorigenicity of stem cells of a mammalian subject, which comprises contacting said stem cell with an effective amount of a fatty acid derivative, are provided. | 12-18-2014 |
20140315994 | METHOD FOR TREATING GASTROINTESTINAL DISORDER - The present invention relates to a method for the long term treatment of gastrointestinal disorders in a human subject, which comprises administering an effective amount of a halogenated prostaglandin compound and/or its tautomer to the subject. The method induces substantially no electrolyte shifting during the term of the treatment. The compound used in the present invention can improve quality of life in the human subjects with gastrointestinal disorders, are similarly effective in treating male and female subjects, and also effective in a human subject aged even 65 years and older. | 10-23-2014 |
20140287036 | SOFT-GELATIN CAPSULE FORMULATION - The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved. | 09-25-2014 |
20140235665 | ANTI-CONSTIPATION COMPOSITION - An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): | 08-21-2014 |
20140066506 | METHOD FOR TREATING MACULAR DEGENERATION - Disclosed is a method for treating macular degeneration in a mammalian subject, which includes administering to the subject in need thereof an effective amount of a 15-keto-prostaglandin compound such as 13,14-dihydro-15-keto-20-ethyl-prostaglandin F | 03-06-2014 |
20140039058 | OPHTHALMIC SOLUTION - The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient. | 02-06-2014 |
20140031428 | METHOD FOR TREATING SCHIZOPHRENIA - The present invention provides a novel fatty acid derivative. The present invention also provides a method for treating schizophrenia in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative. | 01-30-2014 |
20130281638 | TRICYCLO COMPOUND-POLYMER CONJUGATE - A tricycle compound-polymer conjugate including a conjugate comprising a tricyclo compound and an alkyl substituted polylactide compound is provided. A pharmaceutical composition comprising the conjugate is also provided. | 10-24-2013 |
20130281637 | FATTY ACID DERIVATIVE-POLYMER CONJUGATE - A fatty acid derivative-polymer conjugate including a conjugate comprising a fatty acid derivative and an alkyl substituted polylactide compound is provided. A pharmaceutical composition comprising the conjugate is also provided. | 10-24-2013 |
20130281526 | METHOD FOR TREATING IRRITABLE BOWEL SYNDROME WITH DIARRHEA - A method for treating irritable bowel syndrome with diarrhea in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative is provided. | 10-24-2013 |
20130217770 | METHOD FOR TREATING IRRITABLE BOWEL SYNDROME BY ADMINISTRATION OF CHLORIDE CHANNEL OPENER - A chloride channel opener, especially a prostaglandin compound, is used for the treatment of functional gastrointestinal disorders. The prostaglandin compound can be, for example, a 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E | 08-22-2013 |
20130143958 | DOSAGE UNIT COMPRISING A PROSTAGLANDIN ANALOG FOR TREATING CONSTIPATION - A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects. In particular, the dosage unit includes a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein the dosage unit contains the PG analog in a range of about 6-96 μg: | 06-06-2013 |
20130078303 | SOFT-GELATIN CAPSULE FORMULATION - The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved. | 03-28-2013 |
20130035393 | METHOD FOR TREATING SCHIZOPHRENIA - The present invention provides a novel fatty acid derivative. The present invention also provides a method for treating schizophrenia in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative. | 02-07-2013 |
20120277299 | METHOD FOR MODULATING ION TRANSPORTER - The present invention relates to a method for modulating ion transporter or treating disturbances of electrolyte transport during disease state, comprising an administration at a fatty acid derivative to a mammalian subject. The present invention also relates to a composition for modulating ion transporter or treating disturbances of electrolyte transport during disease state, comprising a fatty acid derivative. | 11-01-2012 |
20120270945 | METHOD FOR MODULATING CYTOKINE ACTIVITY - The present invention relates to a method for modulating cytokine activity, immunomodulation or treating esophagitis comprising an administration of a fatty acid derivative to a mammalian subject. The present invention also relates to a composition for modulating cytokine activity, immunomodulation or treating esophagitis comprising a fatty acid derivative. | 10-25-2012 |
20120259008 | METHOD FOR TREATING ASTHENOPIA - The present invention relates to a method for treating asthenopia, accommodative dysfunction or ocular pain comprising an administration of a specific prostaglandin compound to a mammalian subject. The present invention also relates to a composition for treating asthenopia, accommodative dysfunction or ocular pain comprising a specific prostaglandin compound. | 10-11-2012 |
20120237598 | ANTI-CONSTIPATION COMPOSITION - An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): | 09-20-2012 |
20120225938 | METHOD FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS - The present invention provides a method for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin compound to a subject in need thereof. The invention also provide novel 11-deoxy-prostaglandin compound. | 09-06-2012 |
20120095090 | NOVEL COMPOSITION AND METHOD FOR STABILIZING THE SAME - Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride. | 04-19-2012 |
20120088824 | DOSAGE UNIT COMPRISING A PROSTAGLANDIN ANALOG FOR TREATING CONSTIPATION - A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects. | 04-12-2012 |
20120022152 | ANTI-CONSTIPATION COMPOSITION - An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): | 01-26-2012 |
20110300211 | SOFT-GELATIN CAPSULE FORMULATION - The present invention provides a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which includes: a soft gelatin capsule shell including gelatin and sugar alcohol as a plasticizer, and a mixture including a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved. | 12-08-2011 |
20110244037 | PHARMACEUTICAL COMPOSITION COMPRISING A BI-CYCLIC COMPOUND AND METHOD FOR STABILIZING THE BI-CYCLIC COMPOUND - Disclosed is a method for stabilizing a pharmaceutically active bi-cyclic compound of formula (I): | 10-06-2011 |
20110244036 | PHARMACEUTICAL COMPOSITION COMPRISING A BI-CYCLIC COMPOUND AND METHOD FOR STABILIZING THE BI-CYCLIC COMPOUND - Disclosed is a method for stabilizing a pharmaceutically active bi-cyclic compound of formula (I): | 10-06-2011 |
20110065784 | METHOD FOR PROMOTING GASTROINTESTINAL BICARBONATE SECRETION - Provided is a method for promoting gastrointestinal bicarbonate secretion in a mammalian subject, which comprises administering an effective amount of a compound of Formula (I): | 03-17-2011 |
20110064748 | PHARMACEUTICAL COMBINATION AND METHOD FOR TREATING TUMOR - Disclosed is a method for treating tumor in a mammalian subject, which comprises administering a combination of (a) an anti-tumor agent and (b) a fatty acid derivative represented by the formula (I): | 03-17-2011 |
20110034424 | METHOD FOR THE LONG TERM NSAID USE - Provided is a method for the long term treatment of a condition or disease which is one of the indications for NSAID use in a human patient, which comprises administering to the patient a pharmaceutically effective amount of a NSAID and at least 36 mcg per day of cobiprostone or its pharmaceutically acceptable salt, ester, ether or amide. By administering cobiprostone or its pharmaceutically acceptable salt, ester, ether or amide in combination with a NSAID, the patient can receive the NSAID for longer time period. | 02-10-2011 |
20100305203 | METHOD FOR MODULATING CLAUDIN MEDIATED FUNCTIONS - Disclosed is a method for modulating a claudin-mediated function in a mammalian subject which comprises administering to a subject in need thereof an effective amount of a specific fatty acid derivative. The application also discloses a method for treating a dermatological disease and a method for modulating an expression of a claudin in a mammalian subject using the same fatty acid derivative as above. | 12-02-2010 |
20100298424 | METHOD FOR TREATING ABDOMINAL DISCOMFORT - Disclosed is a novel use of a chloride channel opener, especially a prostaglandin compound for the treatment of abdominal discomfort. Further disclosed is a novel use of a chloride channel opener, especially a prostaglandin compound for the treatment of functional gastrointestinal disorders. | 11-25-2010 |
20100274032 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE - Disclosed is a method for preparing a prostaglandin derivative of formula (A): | 10-28-2010 |
20100267832 | METHOD FOR TREATING MACULAR DEGENERATION - Disclosed is a method for treating macular degeneration in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a 15-keto-prostaglandin compound such as 13,14-dihydro-15-keto-20-ethyl-prostaglandin F | 10-21-2010 |
20100204491 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE - Disclosed is a method for preparing a prostaglandin derivative of formula (A): | 08-12-2010 |
20100204489 | METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE - Disclosed is a method for preparing a prostaglandin derivative of formula (A): | 08-12-2010 |
20100204332 | METHOD FOR TREATING A DISEASE OR CONDITION RESPONSIVE TO OPENING OF C1C-2 CHANNEL - Disclosed is a method for prophylactic or therapeutic treatment of a condition or disease responsive to opening of ClC-2 channel, which comprises the step of administrating an effective amount of a ClC-2 channel opener to a subject in need of said treatment. According to the invention, a tissue or organ to be transplanted can also be treated with the ClC-2 channel opener. | 08-12-2010 |
20100087540 | PHARMACEUTICAL COMPOSITION - Provided is a pharmaceutical composition comprising: a) a prostaglandin compound; (b) a sugar alcohol; (c) a polyol; and (d) a pharmaceutically acceptable carrier. The composition of the present invention can be stored stably even in a polyethylene container. In addition, the composition of the present invention can be stored stably for a long term even if it comprises only a small amount of a preserving agent. | 04-08-2010 |
20090209643 | METHOD FOR MODULATING STEM CELL GROWTH - In one embodiment, provided is a composition comprising a prostaglandin compound for modulating stem cell proliferation and/or differentiation in a mammalian subject. In another embodiment, the instant application is a composition comprising a prostaglandin compound for, which comprises a prostaglandin compound for modulating proliferation and/or differentiation of stem cells of a mammalian subject, in which the stem cells are contacted directly or indirectly with the composition of the invention. | 08-20-2009 |
20090022787 | PHARMACEUTICAL COMPOSITION COMPRISING 11-DEOXY- PROSTAGLANDIN COMPOUND AND METHOD FOR STABILIZING THE COMPOUND - Provided is a pharmaceutical composition comprising a 11-deoxy-prostaglandin compound represented by formula (I): | 01-22-2009 |
20090012165 | PHARMACEUTICAL COMBINATION OF NSAID AND PROSTAGLANDIN COMPOUND - Provided is a method for treating a condition or disease which is one of the indications for NSAID use, which comprises administering a combination of:
| 01-08-2009 |
20080221050 | Method for Diagnosing or Predicting Susceptibility to Optic Neuropathy - Disclosed is a set of genetic polymorphisms linked to optic neuropathy including glaucoma and Leber's disease. Those polymorphisms are useful for diagnosing and predicting susceptibility to optic neuropathy. | 09-11-2008 |
20080207759 | METHOD FOR PROTECTING MITOCHONDRIA - The present invention relates to a method for protecting mitochondria from damage in a mammalian subject, which comprises administering an effective amount of a prostaglandin compound to a subject in need thereof. Also provided is a method for treating mitochondrial dysfunction as well as a condition associated with mitochondrial dysfunction in a mammalian subject, which comprises administering an effective amount of a prostaglandin compound to a subject in need thereof. | 08-28-2008 |